First patient receives Vaccitech’s VTP-300 in a Phase 1b/2a clinical trial. An experimental immunotherapy for chronic HBV, a global health problem affecting over 250 million people

February 1, 2021

Stay up to date

Get the latest on cutting-edge developments in our portfolio, straight to your inbox.